Stocktoria
Xilio Therapeutics, Inc. XLO
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-22
Xilio Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — | — |
| R&D expense | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M | $43.9M |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M | -$54.6M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M | -$55.2M |
| EPS (diluted) | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 | $-105.42 |
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M | -$36.1M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M | -$38.3M |
| Cash & equivalents | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M | $19.2M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M | $36.3M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M | $41.6M |
| Shareholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M | -$83.3M |
Growth · year-over-year · Revenue CAGR 589.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +589.9% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.